Alternative in Beta Blocker Intolerance: The ABBI Trial (ABBI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00893984|
Recruitment Status : Terminated (Lack of patient recruitment)
First Posted : May 6, 2009
Last Update Posted : December 9, 2013
In this study the investigators will assess the tolerance of Nebivolol (Bystolic) in cardiovascular patients who are not able to tolerate conventional beta blockers. A side effect profile will be tracked and compared with previous beta blocker use.
The investigators hypothesize that Bystolic will be tolerated by many patients who are intolerant of conventional blockers.
|Condition or disease||Intervention/treatment||Phase|
|Coronary Artery Disease||Drug: Nebivolol||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||6 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Alternative in Beta Blocker Intolerance; the ABBI Trial|
|Study Start Date :||May 2009|
|Primary Completion Date :||June 2012|
|Study Completion Date :||June 2012|
Bystolic (Nebivolol), 5 mg per day for 30 days, titrated up to 10 mg at 2 weeks if necessary for blood pressure control.
Other Name: Bystolic
- Incidence of intolerance of Bystolic, measured by side effect(s) that lead to discontinuance of Bystolic by the patient and/or the physician [ Time Frame: 30 Days ]
- Reason for termination of Bystolic [ Time Frame: 30 Days ]
- Incidence of same symptom stopping Bystolic as previous beta blocker [ Time Frame: 30 Days ]
- Symptom severity [ Time Frame: 30 Days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00893984
|United States, Minnesota|
|Minneapolis Heart Institute at Abbott Northwestern Hospital|
|Minneapolis, Minnesota, United States, 55407|
|Principal Investigator:||Graham||Minneapolis Heart Institute Foundation|